| Similar Articles |
|---|
 |
The Motley Fool
May 27, 2009
Brian Orelli |
A Wrinkle in the Botox Plan The FDA turns down Allergan's label expansion, but it wasn't all bad news.   |
CRM
November 1, 2006
Colin Beasty |
Business Problem: Poor e-mail Response Times Lead to Increased Numbers of Phone Calls to the Contact Center Tech Solution: e-mail management tools. KANA Response... Kintera CRM... Talisma Email... |
BusinessWeek
October 13, 2003
Arlene Weintraub |
He Bet on Botox -- And Won David Pyott transformed sleepy Allergan. Where is he taking its blockbuster drug? |
The Motley Fool
June 5, 2008
Brian Lawler |
Allergan Lashes Out The pharmaceutical announces a new drug that could promote eyelash growth. |
The Motley Fool
September 12, 2008
Brian Lawler |
A New Wrinkle for an Old Drug Allergan's muscle relaxant Botox performs well in two studies testing its ability to prevent migraine headaches. |
Chemistry World
June 10, 2008
James Mitchell Crow |
A Drug for Longer Lashes? US drugmaker Allergan, the California-based company that makes antiwrinkle treatment Botox, has developed a new cosmetic drug that makes eyelashes grow longer, thicker and darker. |
CRM
May 1, 2007
Jessica Sebor |
Gaining Altitude JetBlue implements a Web self-service solution to power customers to field their own questions and let agents focus on the human touch. |
Chemistry World
April 29, 2014
Phillip Broadwith |
Valeant launches hostile bid for Allergan US drugmaker Valeant has lined up its next takeover target: Botox provider Allergan. Valeant has taken its proposal direct to shareholders, but Allergan has activated a 'poison pill' defense to buy time. |
The Motley Fool
May 6, 2009
Robert Steyer |
Getting Ahead by Getting Rid of Wrinkles Medicis gets the FDA OK for an anti-wrinkle product as the market for Botox and other cosmetic skin drugs sags. |
The Motley Fool
January 31, 2007
Brian Lawler |
No Earnings Face-Lift Needed For Allergan The ophthalmic and plastic surgery product developer has made many investors rich, and it's not stopping now. |
The Motley Fool
November 22, 2006
Brian Lawler |
Implant Approval Gives Allergan a Lift The return of silicone breast implants continues. Shares of Allergan, best known for its Botox wrinkle treatment, were up nearly 8% on the news. |
CRM
July 1, 2003
Ramin Ganeshram |
Seeing Green Rob McClellan, director of supply chain management and services for Taylor Made-Adidas Golf, uses email to drive leads to resellers. |
CIO
December 14, 2010
Kim S. Nash |
How Botox Battles Compliance Wrinkles A BPM overhaul saved the day after legal issues complicated compliance at Botox-maker Allergan. |
CRM
September 1, 2005
Coreen Bailor |
Email Response Times Lag Still Many organizations are failing to capitalize on email, allowing sluggish response times to customer inquiries. This runs the risk of tarnishing customer relationships. Companies are nowhere near responding to the channel like they should. |
Chemistry World
June 24, 2015
Matthew Gunther |
Allergan to buy out Kythera Biopharma for $2.1bn The pharma firm Allergan will acquire Kythera Biopharmaceuticals in a $2.1 billion deal. |
The Motley Fool
March 2, 2011
Susmita Chatterjee |
How to Capitalize on the Obesity Epidemic Does broader use of Allergan's Lap-Band signify competition for others? |
The Motley Fool
September 20, 2007
Brian Lawler |
Allergan's Overactive Acquisition Specialty pharma Allergan announced yesterday that it is acquiring privately held Esprit Pharma for $370 million in an all-cash transaction. Investors, take note. |
CRM
March 2010
Christopher Musico |
Email Management You've Got Mail: Despite fits and starts, many still believe email management solutions can deliver on their promise. |
AskMen.com
Eric Santos |
Mastering Email The truth of the matter is, being good at email is an important skill to have. |
The Motley Fool
December 15, 2003
Alyce Lomax |
No Wrinkles for Medicis Medicis Pharmaceuticals announced that the FDA has approved its injectable wrinkle-filling gel, Restylane. Allergan's Botox has found a new competitor in the fountain-of-youth market. |
The Motley Fool
December 29, 2008
Brian Orelli |
Thicker Lashes, Fatter Wallets The Food and Drug Administration approves Allergan's Latisse, a treatment for sparse eyelashes. |
BusinessWeek
December 25, 2006
Palmeri & Weintraub |
Silicone Goes Subtle Allergan's campaign relies on friendly persuasion. |
CRM
April 16, 2013
Kelly Liyakasa |
KANA Software Goes After "Transformational" Enterprise Deployments KANA Enterprise software is tailored for an omnichannel customer experience. |
InternetNews
January 5, 2004
Susan Kuchinskas |
KANA Customers Connected at the Hipbone The CRM specialist's acquisition lets call center reps help customers via live chat and co-browsing. |
The Motley Fool
December 16, 2005
Stephen D. Simpson |
A Romantic Rectangle in Health Care First Medicis wants Inamed, then Allergan wants Inamed. Now Mentor wants Medicis. Strange days in health care, to be sure. Investors, take note. |
Chemistry World
January 25, 2013
Andrew Turley |
Allergan buys MAP for $958m Allergan, best known as the company behind Botox (onabotulinumtoxin A) injections, has agreed to buy US drug maker MAP Pharmaceuticals for $958 million |
AskMen.com
September 15, 2015
Eric Santos |
Sending Great Cold Emails There are plenty of other channels and methods that can be used to acquire customers more effectively, however cold emails can work for you if you do them correctly. |
The Motley Fool
October 7, 2009
Jim Mueller |
Daily Walk of Shame: Money-Hungry Drugmakers If Allergan wins its suit against the government, consumers will really be in trouble. |
BusinessWeek
March 25, 2010
Elizabeth Lopatto |
And Now, Gastric Surgery for Kids Allergan wants to market its Lap-Band implants for younger obese patients, but some doctors are balking |
The Motley Fool
November 17, 2008
Brian Orelli |
Beauty Can Be a Beast Pinched pocketbooks are likely to hurt cosmetic-pharmaceutical companies more than any FDA warning. |
CRM
September 2012
Judith Aquino |
Avoid the Spam Folder How marketers can save outbound emails from the dreaded fate. |
Chemistry World
November 27, 2015
Anthony King |
Pfizer and Allergan agree mega-merger The deal is being positioned as Irish-based Allergan taking over Pfizer, with the merged entity resident in Ireland for tax purposes. |
The Motley Fool
June 23, 2007
Elizabeth Brokamp |
Is Your Email Out of Control? The best strategies for coping with electronic overload. |
InternetNews
March 17, 2008
Rob Lenihan |
KANA Embeds IBM Open Technology IBM and CRM vendor KANA Software are expanding their strategic alliance agreement by jointly marketing, selling and supporting SOA-based customer service solutions, the companies said Monday. |
CRM
April 1, 2004
David Myron |
BPO News & Insight: Email Tuesdays A new report says the most popular day to send an email marketing blast is Tuesday. |
Chemistry World
July 29, 2015
Katrina Megget |
Allergan steps away from generics with sale to Teva In something of a surprise move, Allergan has committed to selling its generics business to Israeli generics giant Teva for $40.5 billion, despite having no prior plans to sell. |
Insurance & Technology
January 28, 2009
Anthony O'Donnell |
MetLife Boosts CSR and IVR Capabilities Competing for external recognition has helped MetLife's call center operations leadership identify the capabilities it needs in order to deliver best-in-class service. |
CRM
July 1, 2009
Lauren McKay |
Dialing into Knowledge For The Carphone Warehouse, the key to quality service is empowering agents with consistent and organized knowledge. |
The Motley Fool
January 15, 2009
Robert Steyer |
Medicis Tries to Save Face The wrinkle-removal drugmaker hopes it can smooth out a tough economy. |
The Motley Fool
August 8, 2006
Stephen D. Simpson |
Waiting on Fine Figures From Mentor Flush with cash, medical aesthetics specialist Mentor needs to reinvest in growth. This is a fine company that rarely trades cheap -- investors, take note. |
Chemistry World
July 28, 2014
Andy Extance |
Takeover battle pushes Allergan to cut R&D jobs Despite a quarterly sales increase it describes as its strongest ever, Botox maker Allergan is laying off 1500 staff as it seeks to fend off a hostile takeover. |
